Instil Bio Inc. Common Stock (TIL)

FairStock Score: 66/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable economics, honest accounting, and a margin of safety. Instil Bio fails the first test. It is a 17-employee biopharmaceutical company with no revenue in the filed periods, and FairStock classifies it in no Lynch category because it lost money in each of the last four years. The losses are large: in fiscal 2025, the year ended 2025-12-31, net loss was $71.4 million and diluted EPS was -$10.70; in fiscal 2024, net loss was $74.1 million and diluted EPS was -$11.39; in fiscal 2023, net loss was $156.1 million and diluted EPS was -$24.00. More recently, fiscal Q2 2026, the quarter ended 2026-06-30, lost $4.3 million, or -$0.63 per diluted share, versus a $21.4 million loss in fiscal Q2 2025. That improvement is welcome, and FairStock's profit-growth figure is 79.91%, but it is still a loss. At the 2026-10-13 close of $6.18 and $41.9 million market cap, FairStock shows P/B of 0.38 and negative P/E of -1.40. A price below book can be attractive, but only if the book value is real and not being consumed. Here trailing free cash flow is -$33.6 million and FCF yield is -80.2%; Piotroski is 1/9 and Altman Z is -4.51. FairStock also shows ROE -25.33%, ROCE -10.77%, and D/E 0.81. Those are distress signals. There is no competitive moat—no product, no revenue, no evidence of pricing power. The stock may be an asset play, but I prefer assets that earn. I see speculation, not a Graham-style bargain.

In plain English: Instil Bio is a small biotechnology company with 17 employees that tries to find or acquire new medicines. It has no reported sales, has lost money for years, and uses cash. The share price is low compared with its accounting value, but the losses make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer